Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0778
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.3590
    -0.0130 (-0.01%)
     
  • Bitcoin USD

    70,334.69
    +582.17 (+0.83%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,360.30
    +192.23 (+0.48%)
     

Lpath to cut jobs as eye drug fails mid-stage study

May 20 (Reuters) - Lpath Inc said it would reduce its workforce and cut costs as its experimental drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.

Lpath's drug, iSONEP, did not show any statistically significant improvement in visual clarity in patients who had not realized enough benefit from prior treatments, the company said on Wednesday.

Lpath said it expects the cost saving initiatives to shore up enough funds for its drug discovery and development activities through June 30, 2016.

(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)

Advertisement